Introduction: Stathmin is a microtubule-destabilizing phosphoprotein, firstly identified as the
downstream target of many signal transduction pathways. Several studies then indicated that …

Preclinical studies demonstrated that complement promotes tumor growth. Therefore, we
sought to determine the best target for complement-based therapy among common human …

… of CD44 in carcinoma potentially offering new molecular target for therapeutic intervention.
… cancer progression as well as the potential CD44-targeting therapy for cancer management. …

… To identify potential biomarkers and/or therapeutic targets for bladder cancer we characterized
and analysed the composition of the urinary microbiota from bladder cancer and non-…

… top five biomarker candidates. … therapeutic target candidates for follicular adenoma, including
TGFB1, MYC, ANGPT2, and NFE2L2. This study provided biomarker and therapeutic target …

… biomarkers for CVD. Furthermore, miRNAs represent potential novel therapeutic targets for
… In addition, the use of miRNA as therapeutic targets is also discussed, as well as challenges …

… Finally, the potential utility of TMAO as therapeutic target is also analyzed. … to study the
potential utility of TMAO as an early biomarker or a target for the prevention of disease in humans. …

… that could potentially serve as a biomarker and therapeutic target for PPCM. … biomarker for
the diagnosis of PPCM in patients and that miR-146a may represent a novel therapeutic target …

… potential value and can become therapeutic targets for cancer diagnosis and treatment. … ,
target silencing of candidate piRNA-823 was provided therapeutic targets for potential clinical …

… potential clinical utility as a biomarker/target for early detection, cancer risk stratification, and
personalized cancer therapies. … further explored as a potential therapeutic target; however, …